v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
ASSETS    
Cash and cash equivalents $ 34,996 $ 2,998
Zydus agreements escrow receivable (Note R) 7,500 0
Zydus transaction contract assets 40,000 0
Accounts receivable 6,562 1,831
Prepaid expenses 4,188 785
Assets held for sale 0 121,554
Other current assets 2,038 1,089
Total current assets 95,284 133,436
Property, plant and equipment, net of accumulated amortization and depreciation of $47,893 and $47,468 at March 31, 2026 and December 31, 2025, respectively 14,947 15,470
Operating lease right-of-use assets 7,458 7,744
Goodwill 24,092 24,092
Acquired intangible assets, net of accumulated amortization of $19,675 and $17,325 at March 31, 2026 and December 31, 2025, respectively 2,959 3,037
Equity method investment in MiNK Therapeutics, Inc. 22,927 24,277
Other long-term assets 3,013 3,307
Total assets 186,456 226,798
LIABILITIES AND STOCKHOLDERS' DEFICIT    
Current portion, long-term debt 30,193 44,655
Current portion, liability related to sale of future royalties and milestones 109,405 109,323
Current portion, operating lease liabilities 1,054 1,034
Accounts payable 71,084 82,987
Accrued liabilities 36,987 34,223
Liabilities held for sale 0 50,738
Other current liabilities 514 529
Total current liabilities 249,237 323,489
Liability related to sale of future royalties and milestones, net of current portion 153,985 169,660
Deferred revenue, net of current portion 1,143 1,143
Operating lease liabilities, net of current portion 9,827 10,108
Other long-term liabilities 247 259
Commitments and contingencies
STOCKHOLDERS" DEFICIT    
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 38,521,761 and 35,320,397 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 385 353
Additional paid-in capital 1,922,370 1,911,740
Accumulated other comprehensive loss (437) (439)
Accumulated deficit (2,143,539) (2,182,765)
Total stockholders' deficit attributable to Agenus Inc. (221,221) (271,111)
Non-controlling interest (6,762) (6,750)
Total stockholders' deficit (227,983) (277,861)
Total liabilities and stockholders' deficit 186,456 226,798
Related Parties [Member]    
ASSETS    
Related party note receivable from MiNK Therapeutics, Inc. 0 5,179
Due from related parties (MiNK Therapeutics, Inc.) 15,776 15,435
Series A-1 convertible preferred stock [Member]    
STOCKHOLDERS" DEFICIT    
Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at March 31, 2026 and December 31, 2025; liquidation value of $34,371 at March 31, 2026 $ 0 $ 0